Format

Send to

Choose Destination
Curr HIV/AIDS Rep. 2016 Feb;13(1):31-7. doi: 10.1007/s11904-016-0299-7.

Broadly Neutralizing Antibodies for HIV Eradication.

Author information

1
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA, 02215, USA.
2
Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
3
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA, 02215, USA. dbarouch@bidmc.harvard.edu.
4
Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA. dbarouch@bidmc.harvard.edu.

Abstract

Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline.

KEYWORDS:

Antibody; Broadly neutralizing antibodies; Eradication; HIV; HIV pathogenesis; HIV/AIDS; Reservoir; Review; bNAb

PMID:
26841901
PMCID:
PMC4779134
DOI:
10.1007/s11904-016-0299-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center